Combination immunotherapy improves survival in mouse models of mesothelioma

Investigators have found that combined treatment with two cancer immunotherapy drugs — one a novel immune modulator and one that focuses and activates the anti-tumor immune response — significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma. (Mehr in: Cancer News — ScienceDaily)